Dry-Coated Live Viral Vector Vaccines Delivered by Nanopatch Microprojections Retain Long-Term Thermostability and Induce Transgene-Specific T Cell Responses in Mice

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Pearson, Frances E ^a,b   McNeilly, Celia L ^a   Crichton, Michael L ^a   Primiero, Clare A ^a   Yukiko, Sally R ^a   Fernando, Germain J P ^a   Chen, Xianfeng ^a   Gilbert, Sarah C ^b   Hill, Adrian V S ^b   Kendall, Mark A F ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DILUENT; DISACCHARIDE; LIVE VACCINE; MALARIA VACCINE; SUCROSE; TREHALOSE; VIRUS VACCINE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL VIABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; HEALTH CARE SYSTEM; IMMUNOGENICITY; MALARIA; MOUSE; NONHUMAN; POXVIRUS; SIMIAN VIRUS; T LYMPHOCYTE; THERMOSTABILITY; VACCINIA; VIRION;

ADENOVIRUSES, SIMIAN; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DERMIS; EPIDERMIS; FEMALE; FREEZE DRYING; GENETIC VECTORS; MALARIA VACCINES; MICE; T-LYMPHOCYTES; TRANSGENES; VACCINE POTENCY; VACCINES, ATTENUATED; VACCINES, DNA; VACCINIA VIRUS;

MURINAE; MUS; POXVIRIDAE; SIMIAN ADENOVIRUS;

EID: 84879985510     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067888     Document Type: Article

References (52)

1. Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M, (1999) Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Organ 77: 789-800.
2. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, (2011) First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. New Eng J Med 365: 1863-1875.
3. Fernando GJ, Chen X, Prow TW, Crichton ML, Fairmaid EJ, et al. (2010) Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model. PloS ONE 5: e10266.
4. Jenkins D, Corrie S, Flaim C, Kendall M, (2012) High density and high aspect ratio solid micro-nanoprojection arrays for targeted skin vaccine delivery and specific antibody extraction. RSC Advances 2: 3490-3495.
5. Crichton ML, Ansaldo A, Chen X, Prow TW, Fernando GJ, et al. (2010) The effect of strain rate on the precision of penetration of short densely-packed microprojection array patches coated with vaccine. Biomaterials 31: 4562-4572.
6. Kask AS, Chen X, Marshak JO, Dong L, Saracino M, et al. (2010) DNA vaccine delivery by densely-packed and short microprojection arrays to skin protects against vaginal HSV-2 challenge. Vaccine 28: 7483-7491.
7. Chen X, Prow TW, Crichton ML, Jenkins DW, Roberts MS, et al. (2009) Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin. J Control Release 139: 212-220.
8. Prow TW, Chen X, Prow NA, Fernando GJ, Tan CS, et al. (2010) Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice. Small 6: 1776-1784.
9. Corbett HJ, Fernando GJ, Chen X, Frazer IH, Kendall MA, (2010) Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model. PloS ONE 5: e13460.
10. Ng HI, Fernando GJ, Kendall MA, (2012) Induction of potent CD8(+) T cell responses through the delivery of subunit protein vaccines to skin antigen-presenting cells using densely packed microprojection arrays. J Control Release 162: 477-484.
11. Hill AV, Reyes-Sandoval A, O'Hara G, Ewer K, Lawrie A, et al. (2010) Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccines 6: 78-83.
12. Draper SJ, Heeney JL, (2010) Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 8: 62-73.
13. Webster DP, Dunachie S, McConkey S, Poulton I, Moore AC, et al. (2006) Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 24: 3026-3034.
14. Brookes RH, Hill PC, Owiafe PK, Ibanga HB, Jeffries DJ, et al. (2008) Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. PloS ONE 3: e2921.
15. Dudareva M, Andrews L, Gilbert SC, Bejon P, Marsh K, et al. (2009) Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine 27: 3501-3504.
16. Tatsis N, Ertl HC, (2004) Adenoviruses as vaccine vectors. Mol Ther 10: 616-629.
17. Capone S, Reyes-Sandoval A, Naddeo M, Siani L, Ammendola V, et al. (2010) Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine 29: 256-265.
18. O'Hara GA, Duncan CJ, Ewer KJ, Collins KA, Elias SC, et al. (2012) Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 205: 772-781.
19. Reyes-Sandoval A, Sridhar S, Berthoud T, Moore AC, Harty JT, et al. (2008) Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur J Immunol 38: 732-741.
20. Chen D, Kristensen D, (2009) Opportunities and challenges of developing thermostable vaccines. Exp Rev Vacc 8: 547-557.
21. World Malaria Report (2011). World Health Organization.
22. Chang LL, Shepherd D, Sun J, Ouellette D, Grant KL, et al. (2005) Mechanism of protein stabilization by sugars during freeze-drying and storage: native structure preservation, specific interaction, and/or immobilization in a glassy matrix? J Pharm Sci 94: 1427-1444.
23. Alcock R, Cottingham MG, Rollier CS, Furze J, De Costa SD, et al. (2010) Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci Trans Med 2: 19ra12.
24. Gilbert SC, Plebanski M, Harris SJ, Allsopp CE, Thomas R, et al. (1997) A protein particle vaccine containing multiple malaria epitopes. Nat Biotech 15: 1280-1284.
25. Aidoo M, Lalvani A, Allsopp CE, Plebanski M, Meisner SJ, et al. (1995) Identification of conserved antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria. Lancet 345: 1003-1007.
26. Mulholland WJ, Arbuthnott EA, Bellhouse BJ, Cornhill JF, Austyn JM, et al. (2006) Multiphoton high-resolution 3D imaging of Langerhans cells and keratinocytes in the mouse skin model adopted for epidermal powdered immunization. J Inv Derm 126: 1541-1548.
27. Moore AC, Hill AV, (2004) Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol Rev 199: 126-143.
28. Bos JD, Meinardi MM, (2000) The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Derm 9: 165-169.
29. Stoitzner P, Tripp CH, Eberhart A, Price KM, Jung JY, et al. (2006) Langerhans cells cross-present antigen derived from skin. Proc Natl Acad Sci U S A 103: 7783-7788.
30. Bedoui S, Whitney PG, Waithman J, Eidsmo L, Wakim L, et al. (2009) Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat Immunol 10: 488-495.
31. Ruutu MP, Chen X, Joshi O, Kendall MA, Frazer IH, (2011) Increasing mechanical stimulus induces migration of Langerhans cells and impairs the immune response to intracutaneously delivered antigen. Exp Dermatol 20: 534-536.
32. Vrdoljak A, McGrath MG, Carey JB, Draper SJ, Hill AV, et al. (2011) Coated microneedle arrays for transcutaneous delivery of live virus vaccines. J Control Release 159: 34-42.
33. Hiraishi Y, Nandakumar S, Choi SO, Lee JW, Kim YC, et al. (2011) Bacillus Calmette-Guerin vaccination using a microneedle patch. Vaccine 29: 2626-2636.
34. Choi HJ, Bondy BJ, Yoo DG, Compans RW, Kang SM, et al. (2012) Stability of whole inactivated influenza virus vaccine during coating onto metal microneedles. J Control Release In Press. DOI: 10.1016/j.jconrel.2012.12.002.
35. Rheinbaben F, Gebel J, Exner M, Schmidt A (2007) Environmental resistance, disinfection, and sterilization of poxviruses. In: Mercer A, Schmidt A, Weber O, editors. Poxviruses: Birkhäuser Basel. 397-405.
36. Berk A (2006) Adenoviridae; Knipe DM, Howley PM, editors: Lippincott Williams & Wilkins.
37. Lloyd J, Technologies for vaccine delivery in the 21st century (2000). Department of Vaccines and Biologicals, World Health Organization.
38. Temperature sensitivity of vaccines (2006). World Health Organization.
39. Edens C, Collins ML, Ayers J, Rota PA, Prausnitz MR (2012) Measles vaccination using a microneedle patch. Vaccine In Press. DOI 10.1016/j.vaccine.2012.09.062.
40. Chen X, Fernando GJ, Crichton ML, Flaim C, Yukiko SR, et al. (2011) Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization. J Control Release 152: 349-355.
41. Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR, (2010) Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release 142: 187-195.
42. Quan FS, Kim YC, Yoo DG, Compans RW, Prausnitz MR, et al. (2009) Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PloS ONE 4: e7152.
43. Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR, (2011) Stability kinetics of influenza vaccine coated onto microneedles during drying and storage. Pharmaceutical research 28: 135-144.
44. Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR, (2010) Formulation of microneedles coated with influenza virus-like particle vaccine. AAPS PharmSciTech 11: 1193-1201.
45. Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR, (2010) Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. Journal of controlled release: official journal of the Controlled Release Society 142: 187-195.
46. Bachy V, Hervouet C, Becker PD, Chorro L, Carlin LM, et al. (2013) Langerin negative dendritic cells promote potent CD8+ T-cell priming by skin delivery of live adenovirus vaccine microneedle arrays. Proc Natl Acad Sci U S A 110: 3041-3046.
47. Carey JB, Pearson FE, Vrdoljak A, McGrath MG, Crean AM, et al. (2011) Microneedle array design determines the induction of protective memory CD8+ T cell responses induced by a recombinant live malaria vaccine in mice. PLoS ONE 6: e22442.
48. Chen X, Corbett HJ, Yukiko SR, Raphael AP, Fairmaid EJ, et al. (2011) Site-selectively coated, densely-packed microprojection array patches for targeted delivery of vaccines to skin. Adv Funct Mater 21: 464-473.
49. Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, et al. (1998) Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4: 397-402.
50. Reyes-Sandoval A, Berthoud T, Alder N, Siani L, Gilbert SC, et al. (2010) Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 78: 145-153.
51. Gilbert SC, Schneider J, Hannan CM, Hu JT, Plebanski M, et al. (2002) Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 20: 1039-1045.
52. Reyes-Sandoval A, Pearson FE, Todryk S, Ewer K, (2009) Potency assays for novel T-cell-inducing vaccines against malaria. Curr Opin Mol Ther 11: 72-80.